New FDA-Cleared Brain Stimulation Treatment Offers Personalized Relief for PTSD

A personalized brain stimulation treatment developed by Wave Neuroscience and researchers at the Texas A&M Health Institute of Biosciences and Technology has received FDA clearance for post-traumatic stress disorder. The system achieved a 52 percent reduction in symptoms and a 68 percent remission rate in clinical trials.

The regulatory milestone gives clinicians a non-medication alternative for patients who do not find relief through traditional care. Approximately 6 percent of Americans will experience post-traumatic stress disorder during their lifetime, with higher rates observed among women and military veterans.

Historical Treatment Standards and Medication Limitations Since 1980

Since post-traumatic stress disorder was formally recognized as a diagnosis in 1980, treatment has largely centered on psychotherapy and selective serotonin reuptake inhibitors, including sertraline and fluoxetine. While these conventional methods help some patients, many continue to experience symptoms despite receiving ongoing care.

A 2020 review of post-traumatic stress disorder medications found that patient symptom assessments improved by 6.8 to 10.1 points, with remission rates reaching only 10.9 percent at most. In comparison, Wave Neuroscience reported substantially stronger preliminary outcomes during its clinical evaluation.

In comparison to that study, our FDA trial reported a 52% reduction in symptoms, so more than a four-fold increase in efficacy. And more importantly, we saw 68% remission in our clinical trial. So, it’s really a quantum change, an inflection point in what we can offer to patients. From a clinical care perspective, that’s really meaningful.

Erik Won

Magnetic e-Resonance Therapy Integration and Regulatory Designation in 2024

The newly cleared platform uses Magnetic e-Resonance Therapy, combining electroencephalogram brain activity measurements with targeted transcranial magnetic stimulation. An AI-assisted multivariate algorithm customizes stimulation protocols based on each individual’s unique electrical signals rather than applying a standardized approach.

The regulatory timeline accelerated significantly when the technology received an FDA Breakthrough Device designation in 2024. Dr. Rick Silva, executive director of clinical trials at the Texas A&M Health Institute of Biosciences and Technology, noted that the designation streamlined administrative communication while maintaining required medical and scientific standards.

Expanding Options Beyond Conventional Psychotherapy

Dr. Israel Liberzon, distinguished professor of psychiatry and behavioral sciences at the Texas A&M Naresh K. Vashisht College of Medicine, served as the lead psychiatrist and post-traumatic stress disorder specialist for the evaluation. He pointed out that psychotherapies often require intense active participation that can cause high dropout rates due to anxiety.

During the clinical evaluation, participants completed five treatment sessions each week over a span of five to six weeks. Researchers observed that symptom improvements persisted after the active therapy sessions concluded, indicating that the therapeutic benefits extend beyond the treatment period.

Future Availability and Insurance Coverage Expansion

Wave Neuroscience and Texas A&M Health are collaborating with other industry stakeholders to expand market access and secure insurance coverage that makes the therapy more affordable for patients. Dr. Kenneth S. Ramos, a physician-scientist at Texas A&M Health, emphasized that precision medicine approaches aim to align medical care with the biological characteristics of individual patients.

Additional clinical findings from the trial are currently being prepared for public release.